iiinova — where your digital self keeps evolving

Reposted by Professor Sarosh Irani

Nuffield Department of Clinical Neurosciences @ndcnoxford.bsky.social · 30/04/2025

Many congratulations to Professor Irani and co-authors for winning the prestigious 2024 PNAS Cozzarelli Prize in Biomedical Science. 👏🧠 The winning paper was a collaboration between NDCN, The Department of Statistics, and the Mayo Clinic in Florida.

Binding of live hippocampal neurons by monoclonal antibodies created from a cerebrospinal fluid plasmablast extracted from an encephalitis patient

131

Professor Sarosh Irani @mayo-aing.bsky.social · 09/03/2025

Reminder to all interested in #autoimmune #neurology Please join us ce.mayo.edu/neurology-and-… For great weather, faculty talks and networking….. This will be a small, focused meeting for you to develop your knowledge and skills in #autoimmune #neurology

ce.mayo.edu

020

Professor Sarosh Irani @mayo-aing.bsky.social · 28/02/2025

onlinelibrary.wiley.com/doi/full/10.10… Here is the first PROM (patient reported outcome measure) for patients with #LGI1 antibody #encephalitis Hopefully a major inroad to measuring this disease more carefully 👍 We hope this will help patients in routine practice, and in trials

onlinelibrary.wiley.com

140

Professor Sarosh Irani @mayo-aing.bsky.social · 08/02/2025

#world #encephalitis #day #america 🇺🇸 #WEDA is today!! On the Mayo JAX campus @MayoClinic @MayoClinicNeuro Kicked off by Philippa Chapman of encephalitis international

220

Reposted by Professor Sarosh Irani

Professor Sarosh Irani @mayo-aing.bsky.social · 03/02/2025

In 3 months (and zero days), we have the inaugural @MayoClinic #florida #autoimmune #neurology meeting. 1.5 days of great speakers and 0.5 days to spend on the beautiful Jacksonville beach 🏖️ Please sign up now ✍️ ce.mayo.edu/neurology-an...

ce.mayo.edu

031

Professor Sarosh Irani @mayo-aing.bsky.social · 03/02/2025

ce.mayo.edu

031

Professor Sarosh Irani @mayo-aing.bsky.social · 19/01/2025

Our new CASPR2 paper is out in Annals Neurology 🤩 Headlines: Patients have neuropathic pain & fatigue as their main long term complaints which determine QoL. 😰 These are NOT immunotherapy responsive. 👩🏾‍⚕️💊 We also report other nuggets in this thread 🧵 ⬇️ onlinelibrary.wiley.com/doi/10.1002/...

onlinelibrary.wiley.com

Immunotherapy‐Resistant Neuropathic Pain and Fatigue Predict Quality‐of‐Life in Contactin‐Associated Protein‐Like 2 Antibody Disease

The long-term clinical outcomes and associated prognostic factors in contactin-associated protein-like 2 (CASPR2)-antibody diseases are unknown. A total of 75 participants with CASPR2 antibodies were...

142